In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The visceral adiposity index predicts cardiovascular events both in cardiovascular disease patients with and in those without diabetes

Session Poster Session 2

Speaker Christoph Saely

Event : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Prevention – Cardiovascular Risk Assessment: Scores
  • Session type : Poster Session

Authors : CH Saely (Bern,CH), A Vonbank (Feldkirch,AT), C Heinzle (Feldkirch,AT), D Zanolin (Feldkirch,AT), B Larcher (Feldkirch,AT), A Mader (Feldkirch,AT), A Leiherer (Triesen,LI), A Muendlein (Feldkirch,AT), H Drexel (Philadelphia,US)

C.H. Saely1 , A. Vonbank2 , C. Heinzle3 , D. Zanolin3 , B. Larcher2 , A. Mader2 , A. Leiherer4 , A. Muendlein3 , H. Drexel5 , 1Bern University Hospital, Division of Angiology, Swiss Cardiovascular Center - Bern - Switzerland , 2Academic Teaching Hospital, Department of Medicine and Cardiology - Feldkirch - Austria , 3VIVIT Institute - Feldkirch - Austria , 4Private University of the Principality of Liechtenstein - Triesen - Liechtenstein , 5Drexel University College of Medicine - Philadelphia - United States of America ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 293

Background: The Visceral Adiposity Index Predicts Cardiovascular Events Both in Cardiovascular Disease Patients With and in those Without Diabetes. The visceral adiposity index (VAI) is a validated tool for the evaluation of visceral adiposity, using waist circumference, serum triglycerides, age and gender to diagnose this metabolic abnormality. It has recently been associated with cardiovascular risk in primary care patients.

Purpose: The purpose of this study was to investigate the association of the VAI with mortality in patients with cardiovascular disease (CVD).

Methods: We therefore prospectively recorded the incidence of cardiovascular events over a mean follow-up period of 7.9±3.1 years in a large cohort of 1858 consecutive patients with established cardiovascular disease (1599 patients with angiographically proven coronary artery disease and 259 patients with sonographically proven peripheral artery disease). The VAI was calculated according to the Amato formula; type 2 diabetes (T2DM) was defined according to the ADA definition.

Results: At baseline, the VAI was significantly higher in CVD patients with T2DM than in those who did not have diabetes (347±331 vs. 228±200; p<0.001). Prospectively, 585 vascular events occurred; the event rate was significantly higher in patients with T2DM than in those who did not have diabetes (46.8% vs. 31.3%; p<0.001). After multivariate adjustment, the VAI significantly predicted cardiovascular events in CVD patients with T2DM (standardized adjusted hazard ratio (HR) 1.24 [1.09–1.42]; p=0.007) as well as in those who did not have T2DM (HR 1.18 [1.06–1.31]; p=0.014).

Conclusion: We conclude that the VAI predicts cardiovascular events both in CVD patients with and in those without diabetes.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are